Digest

Edit Biotech financings and M&A

Changes here affect future generations only. Existing episode snapshots stay unchanged.

Reporter name

Topic description

Detailed reporting instructions

Topics include public newco launches with >$10M capital, VC private equity raises of >$30M, IPOs, PIPEs for pre-commercial assets >$50M, VC fund raises of >$100M for biotech funds, licensing deals with >$50M upfront or >$2B total value, acquisitions for >$200M. Commentary should include details on the company, lead asset (including target, modality, stage of development, recent readouts, and upcoming readouts), disease / mechanism, names of investors. Should be tailored to a biotech VC investor as the audience. Should prioritize size of financings and scale of press impact, as well as relevance to preclinical and early clinical private oncology biotech finance. Should have a particular focus on oncology companies. Should have a particular focus on preclinical and clinical stage therapeutics companies. Should cover all modalities. Should include any thoughts / insights on the rationale behind the investment or acquisition, including any analyst commentary. Should include details about the target and disease biology, and how the drug is proposed to work mechanistically.

Preferred source types or domains

Excluded source types or domains

Desired candidate story count

Depth setting

News horizon

Controls how far back this reporter should look when prioritizing current news.

Include this reporter in future briefing generations